XNAS · Healthcare · Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.51 | -0.54 | -5.88% | $206,000 | ❌ Miss | +0.83% | -0.88% | — |
| 2026-03-27 | Q4 2025 | -0.52 | -0.58 | -11.54% | $256,000 | ❌ Miss | +1.46% | -6.35% | -13.49% |
| 2025-11-12 |
| Q3 2025 |
| -1.42 |
| -2.18 |
| -53.52% |
| $98,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -1.86 | -2.45 | -31.72% | $120,000 | ❌ Miss | +9.22% | -27.65% | -50.15% |
| 2025-03-27 | Q4 2024 | -4.96 | -3.57 | +28.02% | $366,000 | ✅ Beat | -8.23% | -21.21% | -15.15% |
| 2024-11-14 | Q3 2024 | -7.68 | -5.12 | +33.33% | $214,000 | ✅ Beat | +9.20% | +9.65% | -21.91% |
| 2024-08-06 | Q2 2024 | -11.36 | -3.36 | +70.42% | $1.1M | ✅ Beat | -5.06% | -27.60% | -38.53% |
| 2024-03-12 | Q4 2023 | -14.56 | -12.16 | +16.48% | $376,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.